Phase I Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders.

Trial Profile

Phase I Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Haematological malignancies
  • Focus Adverse reactions; Registrational
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to a Bellicum Pharmaceuticals media release, the company expects to report top-line results this study and a planned observational trial in pediatric patients receiving transplants from matched unrelated donors (MUD) without BPX-501 in the second half of 2018 with MAA filings planned for 2019.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results (n=38) presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top